Kevin Dugan Published in European Intellectual Property Review
NEW YORK, New York. (January 19, 2011) - Lathrop & Gage attorney Kevin Dugan (Intellectual Property – New York) was recently published in European Intellectual Property Review, the leading international journal in the intellectual property field. In the article, “The Shared Concern of Trade Mark Law and FDA to Avoid Medication Errors,” Dugan discusses the FDA’s trademark review position pertaining to pharmaceutical trademarks and the effect that the application of the Lanham Act should have on the process. Click here to view the article.
Mr. Dugan is former Managing Counsel, Trademarks and Copyrights for Merck & Co., Inc., where he managed Merck’s worldwide trademark and copyright portfolio including leading pharmaceutical brands such as JANUVIA, GARDASIL, SINGULAIR, and ISENTRESS, and copyrights in world-recognized works such as The Merck Manual and The Merck Index. Mr. Dugan has extensive experience in all aspects of U.S. and international trademark, copyright, and unfair competition law and he has held leadership roles in the International Trademark Association (INTA) and The Pharmaceutical Research and Manufacturers of America (PhRMA).
About Lathrop & Gage:
A full-service law firm, Lathrop & Gage LLP has more than 300 attorneys in 11 offices nationwide – from Los Angeles to New York. In 2010, Chambers USA ranked Lathrop & Gage’s corporate, environmental, intellectual property, labor and employment, litigation, real estate and transportation teams among the best in their regions. For more information, visit www.lathropgage.com.